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a b s t r a c t
The most recent guidelines for the treatment of ST elevation myocardial infarction strongly
support a prompt mechanical reopening of the occluded culprit coronary artery. However,
there is a great debate regarding how to treat the bystander non-culprit coronary artery
disease. While data from retrospective studies and registries suggest that it should be
treated in a second-staged procedure, a recent randomised study has suggested a better
outcome for patients receiving complete revascularisation during the index primary PCI. In
this paper we aim to address this controversial point, analysing the most recent and
important scientiﬁc publications and trying to give a personal point of view according to
the clinical practice in our institution.
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ST elevation myocardial infarction (STEMI) represents the
most challenging scenario among the spectrum of acute
coronary syndromes: if the urgent ﬂow restoration of the
occluded coronary artery signiﬁcantly reduces complications,
decreases mortality and improves outcomes, conﬂicting data
exist regarding the best management of bystander non-culprit
lesions.
According to the available literature, the prevalence of
signiﬁcant multi-vessel coronary disease among patients with
STEMI varies from 30% to 60% [1–4].
In the following pages we aim to address this controversial
point, analysing the most recent and important scientiﬁc
publications and trying to give a personal point of view
according to the clinical practice in our institution.
What do the guidelines say
The 2012 European Society of Cardiology (ESC) guidelines on
management of STEMI states that ‘‘Primary percutaneous
coronary intervention (PCI) should be limited to the culprit
vessel with the exception of cardiogenic shock and persistent
ischaemia after PCI of the supposed culprit lesion – Class IIa of
recommendation, Level of evidence A’’ [5].
The same approach is indicated by the more recent
American Heart Association (AHA) guidelines, according to
which ‘‘PCI is indicated in a noninfarct artery at a time
separate from primary PCI in patients who have spontaneous
symptoms of myocardial ischemia (Class I, Level C)’’. Lower
class of recommendation is given in case of ‘‘patients with
intermediate or high-risk ﬁndings on noninvasive testing’’, for
whom ‘‘PCI is reasonable in a noninfarct artery at a time
separate from primary PCI (Class IIa, Level C)’’ [6].
An important aspect to be taken into account, though, is
that the recommendations coming from the cited guidelines
are on the basis of retrospective or observational studies, while
evidence from randomised studies are poor.
Data from retrospective studies and registries
Multi-vessel PCI in the same setting is worse than single-
vessel PCI
To date, the largest dataset comes from the United States
National Cardiovascular Data Registry. Cavender et al. [7]
retrospectively analysed 31,681 patients with STEMI and
multi-vessel coronary disease undergoing primary PCI be-
tween 2004 and 2007. The authors compared the outcome of
patients undergoing multi-vessel PCI during the index
catheterisation (N = 3134) with patients undergoing single-
vessel PCI of the infarct-related artery (IRA) (N = 25,802), afterexcluding patients who underwent staged PCI or left main PCI
(N = 2745). Of note, the analysis included patients with
cardiogenic shock, for whom current guidelines suggest, if
possible, complete revascularisation. The overall in-hospital
mortality rate was greater in patients undergoing multi-vessel
PCI than the single-vessel PCI of the IRA group (7.9% vs. 5.1%,
p < 0.01). Interestingly, the same result was found considering
only the patients with cardiogenic shock, after adjusting for
potential confounders (OR 1.54, 95% CI 1.22–1.95, p < 0.01).
Adjusted analysis for patients without cardiogenic shock
failed to prove a statistically signiﬁcant increased mortality
risk in the multi-vessel PCI group vs. the single-vessel PCI
group. Similar results come from another STEMI registry, the
EUROTRANSFER, a multi-centre European registry [8].
A post hoc analysis of the APEX-AMI (Assessment of
Pexelizumab in Acute Myocardial Infarction) trial showed that
PCI of the signiﬁcant non-culprit lesion performed in the same
setting of the index primary PCI has worse outcomes at 90 days
follow-up than a single-vessel PCI of the IRA (12.5 vs. 5.6%, p
(log-rank) < 0.001 for death and 17.4 vs. 12.0%, p(log-rank)
= 0.020 for the composite endpoint of death/CHF/shock).
Different results come from a recently published analysis of
the AMIS registry (Acute Myocardial Infarction in Switzerland)
[9]. Even if the overall incidence of in-hospital mortality was
signiﬁcantly higher in the multi-vessel PCI group than in the
group of single-vessel PCI of the IRA (7.3% vs. 4.4%, p < 0.001),
this difference disappeared after stratifying patients by risk
(22.2% vs. 21.7%, p = 1.00 in high-risk patients and 2.0% vs. 2.0%
in low-risk patients). Also, the study showed that multi-vessel
disease STEMI patients who underwent complete revascular-
isation were more likely to have a higher risk proﬁle (left-main
involvement, out-of-hospital cardiac arrest or higher Killip
class).
Staged multi-vessel PCI is better than one-time multi-vessel
PCI
If registry data seem to be in favour of a single-vessel PCI of the
IRA during the index procedure, a complete revascularisation
seems to perform better when performed as a staged
procedure.
A retrospective review of the New York State's Percutane-
ous Coronary Interventions Reporting System analysed 4024
multi-vessel disease patients admitted with STEMI and
undergoing primary PCI between 2003 and 2006 [10]. For
patients without haemodynamic compromise, a single-vessel
PCI of the IRA strategy was associated with lower in-hospital
mortality than multi-vessel PCI during the index procedure
(0.9% vs. 2.4%, p < 0.04). There was a lower mortality rate
among patients who underwent staged PCI within 60 days
after the index procedure than patients undergoing single-
vessel PCI of the IRA.
A recent analysis of a European registry, the Western
Denmark Heart Registry, showed that multi-vessel PCI in
the acute setting is associated with higher mortality than
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after the index procedure [11]. Similar results came from a post
hoc analysis of the HORIZONS-AMI trial, where multi-vessel
PCI in the acute procedure was found to be signiﬁcantly
associated with higher 1-year mortality, cardiac mortality and
stent thrombosis than a staged multi-vessel PCI [12].
Staged PCI for signiﬁcant non-culprit lesions seems to
guarantee better outcomes irrespective of when the staged
procedure is performed. Indeed, Chen et al. [13] have
demonstrated that in 561 multi-vessel disease STEMI patients
a staged complete revascularisation signiﬁcantly reduced 1-
year mortality in comparison with single-vessel PCI of the
infarct-related artery (OR 0.29, 95% CI 0.15–0.53, p < 0.0001).
The beneﬁt was present when the staged PCI was performed
either early (<1 month from the index procedure) or late (<6
months).
Data from randomised studies
Surprisingly, the data coming from the few randomised
studies published so far go against the evidence cited in the
previous paragraphs.
A 10-year-old study published by Di Mario et al. [14] showed
that a multi-vessel treatment approach in the setting of
primary PCI was safe in comparison with the approach of a
single-vessel PCI of the IRA, with a similar rate of in-hospital
major adverse cardiac events (0% in single-vessel PCI and 3.8%
in multi-vessel PCI, p = NS). Nevertheless, the authors ob-
served that, when only the culprit lesion was initially treated,
the need for subsequent clinically driven revascularisation
remained low and no clinical or economical advantages were
obtainable with a more aggressive initial approach. The
absence of MACEs in the single-vessel PCI group and the
low incidence in the multi-vessel PCI group do not reﬂect the
common clinical practice and are explained by the very small
population of the study (N = 69).
Politi et al. [15] randomised 214 consecutive patients with
STEMI and multi-vessel disease to undergo either complete
revascularisation during the index catheterisation, or single-
vessel PCI of the IRA or staged multi-vessel PCI and follow
them up for 2.5 years. The patients undergoing single-vessel
PCI were more likely to experience major adverse cardiac
events (MACEs) at follow-up than the other groups (50% vs.
20% vs. 23.1%, p < 0.001). No difference in terms of MACEs was
observed among patients with multi-vessel PCI, either in the
same or in a staged procedure.
In 2013 was presented the ‘‘Randomized Trial of Preventive
Angioplasty in Myocardial Infarction’’ (PRAMI) [16]. In this
multi-centre UK-based trial, the authors enrolled 465 patients
with multi-vessel coronary disease undergoing primary PCI.
To be considered eligible, patients had to present with one or
more stenoses of >50% in the non-culprit artery and had to be
suitable either for the preventive or no-preventive approach,
according to operator's discretion.
Patients have been randomised to receive either multi-
vessel PCI in the same setting of the primary PCI (preventive
PCI group, N = 234) or infarct-related artery only PCI (no
preventive PCI group, N = 231). After the randomisation the
patients have been followed up for a mean time of 23 monthsto evaluate the incidence of the primary composite outcome of
death from cardiac causes, nonfatal myocardial infarction or
refractory angina.
The trial has been stopped prematurely because of the
increased incidence of the primary endpoint in the preventive
PCI group (HR in the preventive-PCI group, 0.35; 95% conﬁ-
dence interval [CI] 0.21–0.58, p < 0.001). The preventive PCI
strategy performed better for all the single components of the
primary endpoint, except for the cardiac death outcome,
where the difference among groups was not statistically
signiﬁcant.
However, several controversial aspects of the trial need to
be highlighted. First, the decision of considering eligible a
patient was entirely left to operators discretion and that might
have caused bias due to inter-observer variability and different
personal practice. Before randomisation, 286 patients have
been excluded because of the presence of left-main or
equivalent disease, chronic total occlusion in the non-infarct
artery or due to a failure in re-opening the infarct-related
artery (as per study protocol), while 269 patients have been
excluded because the non-infarct artery was considered
‘‘unsuitable for PCI’’. What are the features that led the
operators to judge those arteries not suitable for PCI? Without
this information the suspect of the presence of an operator
discretion-based bias is high. Second, the authors did not
report the distribution of important elements which are well-
known predictors of poor prognosis in STEMI (Killip class,
anaemia, maximum elevation in enzymes, door-to-balloon
time, left ventricular ejection fraction, and creatinine level)
[17]. Third, there are no details regarding the characteristics of
the coronary lesions in the non-culprit arteries (a critical
stenosis left in the proximal left anterior descending artery has
worse prognosis in comparison with a critical stenosis in the
distal right coronary artery) [18]. Fourth, no data are available
regarding the outcome of the non-invasive functional tests
performed in 81 patients of the no preventive PCI group and in
39 patients of the preventive PCI group. Fifth, a careful look to
the medical treatment reveals that the majority of patients
had just one single anti-ischaemic agent (mainly beta-
blockers). Since one of the endpoint was the presence of
refractory angina, it is possible that not all the patients have
been treated with optimal anti-anginal medical treatment.
Finally, the strategy proposed by PRAMI seems to be unfeasible
in the daily practice, especially in high-volume centres.
Indeed, performing a multi-vessel PCI can signiﬁcantly
increase the duration of the procedure and that might
represent an issue in case of other impending emergencies.
This is especially true during the night shifts, where the on-call
team's performance can be lower and the back-up in case of
complications might be sub-optimal.
In conclusion, PRAMI has the indisputable merit to be the
biggest trial trying to address a topic for which very few
randomised data are available. Nevertheless, we believe that,
in presence of bystander angiographically signiﬁcant coronary
artery disease, the option of medical treatment only is not
appropriate. It does not reﬂect the common clinical practice,
where, if doubts regarding bystander lesions arise during the
index procedure, patients are sent for functional tests to assess
inducible ischaemia rather than being left on medical
treatment alone.
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In 2011 Vlaar et al. retrospectively reviewed 40,280 cases with
STEMI and multi-vessel coronary artery disease undergoing
PCI. The following strategies have been evaluated: (1) IRA only
PCI, (2) multi-vessel PCI in the index procedure and (3) staged
PCI for the signiﬁcant non-culprit lesions. The authors
reported a clear beneﬁt for the staged PCI strategy as regards
the primary endpoint of short-term mortality, compared with
the single-vessel PCI of the IRA strategy (OR: 3.03, 95% CI 1.41–
6.51, p < 0.005) and with the multi-vessel PCI strategy (OR: 5.31,
95% CI 2.31–12.21, p < 0.0001) [19].
A more recent meta-analysis conﬁrmed this concept; in
case of STEMI and multi-vessel disease, a complete revascu-
larisation strategy during the primary PCI was associated with
an increased in-hospital mortality (OR 1.35, 95% CI 1.19–1.54,Fig. 1 – A 52-year-old man admitted with an inferior ST elevation 
his right coronary artery (panels A and B). A bystander critical s
successfully treated with a staged PCI 5 days later after the indep < 0.001). On the contrary, a multi-vessel PCI performed in a
staged-fashion resulted in a reduced in-hospital mortality (OR
0.35, 95% CI 0.21–0.59, p < 0.001; p interaction <0.001) [20].
Importantly, the above-discussed meta-analyses did not
include PRAMI results.
Our personal point of view
Finding the best treatment in the STEMI setting is challenging.
The presence of more potent antithrombotic agents along
with a more diffuse adoption of the radial approach to reduce
bleeding, opens new options to improve patients' outcomes.
As regards the culprit lesion, the clinical context of STEMI and
the extensive thrombotic burden may require a combination of
mechanical and aggressive pharmacological approach. The
recently published DEFER-STEMI trial [21] has proven anmyocardial infarction underwent a successful primary PCI to
tenosis in the mid left anterior descending artery was then
x presentation (panels C and D).
Table 1 – Ongoing randomised studies in STEMI patients with multi-vessel PCI.a
CVLPRIT (UK) N = 300 Complete in-hospital revascularisation versus culprit only + conservative strategy
PRAGUE-13 (Czech Republic) N = 400 Complete staged revascularisation versus culprit only + conservative strategy
CROSS-AMI (Spain) N = 400 Complete staged revascularisation versus culprit only + stress echo guided
revascularisation
COCUA (Korea) N = 646 Complete acute revascularisation versus culprit only + staged revascularisation
strategy
COMPARE-ACUTE
(Europe and Asia)
N = 885 FFR guided complete (sub) acute revascularisation versus culprit only + conservative
strategy
DANAMI-III (Denmark) N = 2000 3  2 factorial design – culprit vessel PCI with DES versus culprit vessel thrombectomy
with balloon angioplasty – primary PCI with or without post-conditioning – complete
revascularisation versus culprit only
COMPLETE (USA and Canada) N = 3900 Complete revascularisation (acute or staged) versus culprit only + conservative
strategy
a Reprinted from Smits [27], with permission from Europa Digital & Publishing.
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after the mechanical ﬂow restoration in the culprit artery,
leaving the patients on GpIIb/IIIa inhibitors + low molecular
weight heparin and deferring stenting in a second-staged
procedure reduced the risk of no-reﬂow and increased the
myocardial salvage in comparison with an immediate stenting
strategy. Nevertheless, 2 out of 52 patients in the deferred PCI
group experienced a re-occlusion of the infarct-related artery
and this outcome highlights the major limitation of this
strategy.
As regards the non-culprit lesions, if a complete revascu-
larisation before the discharge seems to be an obvious
strategy in case of a patient with a critical bystander proximal
LAD stenosis and long-standing history of angina preceding
the myocardial infarction (Fig. 1), the choice becomes more
difﬁcult in case of intermediate bystander coronary artery
disease in patients with no previous cardiac history or
symptoms. The key decisional factor in the latter case is
represented, in case of asymptomatic patients, by the proof of
inducible ischaemia on functional tests, where the PCI option
is superior to medical treatment only [22].
The decision is even more challenging because the
visual angiographic inspection has been demonstrating its
weakness as a predictor of either the functional signiﬁcance
or subsequent cardiovascular events in asymptomatic
patients.
The FAME trial (Fractional Flow Reserve versus Angiogra-
phy for Guiding Percutaneous Coronary Intervention) [23] has
demonstrated the superiority of the fractional ﬂow reserve-
guided approach over the angiographic-guided approach in
stable patients with multi-vessel coronary artery disease; 2-
year rates of mortality or myocardial infarction were 12.9% in
the angiography-guided group and 8.4% in the FFR-guided
group ( p < 0.02). Interestingly, 37% of the lesions judged
signiﬁcant on the angiographic assessment (>50% of stenosis)
had an FFR of less than 0.80.
An FFR-guided approach for non-culprit lesions in primary
PCI and multi-vessel coronary artery disease could be a
feasible and valid approach but needs to be validated by big
randomised trials [24,25].
As shown by Stone et al. in the PROSPECT trial (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) [26], over a follow-up of 3 years, only the 11.6%of 697 patients with acute coronary syndrome and bystander
coronary artery disease developed a subsequent major
adverse cardiovascular event caused by any of the non-culprit
lesions. More importantly, the majority of these lesions were
mild (less than 30% stenosis) on the basis of visual assessment
at the index angiography.
In our centre, the treatment for STEMI patients with multi-
vessel coronary artery disease does not differ from what is
recommended by the current guidelines and follows a careful
‘‘patient-tailored’’ approach. Excluding the very complex cases
with cardiogenic shock, we do not tend to perform a multi-
vessel PCI during the index catheterisation, where we ‘‘just’’
aim to restore ﬂow in the culprit artery and stabilise the culprit
lesion.
The following step to treat bystander coronary artery
disease can be either completing the revascularisation during
the index hospitalisation, re-assessing the angina burden at an
early follow-up visit or, if needed, performing a functional test
in order to guide any further intervention.
Future perspectives
Several ongoing randomised studies (Table 1) will deﬁnitely
provide a great contribution to this topic [27]. Hopefully, they
will give an answer to the current unmet needs in the
treatment of STEMI patients with multi-vessel coronary artery
disease.
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